More than 7 million Americans are now living with Alzheimer’s disease. The Alzheimer’s Association’s 2026 Facts and Figures report puts the number at 7.4 million Americans age 65 and older living with Alzheimer’s dementia — roughly 1 in 9 people in that age group. That figure deserves one important clarification: it counts only adults 65 and older, not the full population, so the true all-ages total is somewhat higher once younger-onset cases are included. But even stated conservatively, the milestone is unmistakable. Alzheimer’s has become one of the defining public health challenges of an aging America.
To put the number in perspective, 7.4 million is larger than the population of Arizona. Consider what that looks like at street level: in a typical suburban retirement community of 900 residents over 65, statistics suggest roughly 100 of them are living with Alzheimer’s dementia — enough to fill every seat in the community’s dining hall. And because 74 percent of people with the disease are 75 or older, the concentration grows sharply in the oldest neighborhoods, assisted living facilities, and church congregations across the country. The 2026 data also shows where the disease is heading. Absent medical breakthroughs that prevent, slow, or cure Alzheimer’s, the number of Americans 65 and older with the disease is projected to reach 13.8 million by 2060 — nearly double today’s total.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How Many Americans Have Alzheimer’s in 2026, and Who Is Most Affected?
- Alzheimer’s Deaths Are Rising While Other Major Killers Decline
- The Cost of Dementia Care in 2026 — Two Very Different Price Tags
- New Treatments and Blood Tests — What Patients Can Actually Access Now
- What the Statistics Miss — Undercounting, Underdiagnosis, and the 65+ Caveat
- The Caregiver Statistics Behind the Patient Statistics
- State and Regional Variation in Alzheimer’s Deaths
- Frequently Asked Questions
How Many Americans Have Alzheimer’s in 2026, and Who Is Most Affected?
The headline figure — 7.4 million Americans age 65 and older — comes from the Alzheimer’s Association’s annual Facts and Figures report, published in the journal Alzheimer’s & dementia. About 11 percent of the 65-and-older population has Alzheimer’s dementia, which is why the “1 in 9” shorthand appears so often in coverage of the disease. Age remains the single strongest risk factor: nearly three-quarters of people living with Alzheimer’s are 75 or older. The disease does not affect all Americans equally.
Almost two-thirds of Americans with Alzheimer’s are women. Part of that gap reflects longevity — women live longer on average, and age drives risk — but the imbalance is large enough that researchers continue to study whether biological and social factors play additional roles. Racial and ethnic disparities are also stark: older Black Americans are roughly twice as likely, and older Hispanic Americans about 1.5 times as likely, as older White Americans to have Alzheimer’s or another dementia. A useful comparison is to think of Alzheimer’s prevalence the way public health officials think of diabetes a generation ago: a chronic condition so common in older adults that nearly every extended family will encounter it. One in three older adults dies with Alzheimer’s or another dementia — not necessarily from it, but with it present, complicating care at the end of life.
Alzheimer’s Deaths Are Rising While Other Major Killers Decline
The mortality data in the 2026 report tells a story that runs against the broader trend in American medicine. In 2024, the most recent year with death-certificate data, 116,022 deaths were officially attributed to Alzheimer’s disease. Between 2000 and 2024, reported Alzheimer’s deaths rose 134 percent. Over that same quarter century, deaths from stroke, heart disease, and HIV all declined — a testament to prevention and treatment advances that Alzheimer’s has not yet matched.
There is an important limitation in interpreting these numbers. Death-certificate counts almost certainly understate Alzheimer’s true toll, because people in late-stage dementia often die of pneumonia, sepsis, or complications of immobility, and those proximate causes are what get recorded. The 134 percent increase also partly reflects better diagnosis and more willingness to list Alzheimer’s on death certificates, not purely a surge in underlying disease. One caution on rankings: Alzheimer’s is frequently described as a top-ten cause of death in the United States, and some sources have called it the sixth-leading cause for 2024. CDC rankings shift year to year, however, so any specific rank should be checked against current CDC and National Center for Health Statistics data rather than repeated from secondary coverage.
The Cost of Dementia Care in 2026 — Two Very Different Price Tags
The Alzheimer’s Association projects that health and long-term care costs for people living with dementia will reach $409 billion in 2026, on a path toward nearly $1 trillion by 2050. Medicare and Medicaid cover about 75 percent of those costs, which makes dementia one of the largest long-term pressures on both programs. For an individual family, the costs show up as memory-care facility bills that commonly run several thousand dollars a month, home health aides, and out-of-pocket spending that Medicare does not cover. A separate study from the USC Schaeffer Center, published in June 2026, estimated the total cost of dementia in the United States at roughly $818 billion for 2026. That is not a contradiction of the Alzheimer’s Association figure — it is a broader accounting.
The USC analysis found that only about 27 percent of dementia’s total cost flows through the formal health care system; the rest is borne by families, largely in the form of unpaid caregiving and lost income. The two numbers measure different things and should not be conflated: $409 billion captures formal health and long-term care spending, while $818 billion attempts to price the full economic burden. The unpaid side of that ledger is enormous on its own. According to the 2026 report, unpaid caregivers — mostly spouses and adult children — provided more than 19 billion hours of care, valued at over $446 billion. A daughter who cuts back to part-time work to manage her father’s medications, appointments, and wandering episodes is invisible in most health care spending data, but she is exactly where most of dementia’s real cost lands.
New Treatments and Blood Tests — What Patients Can Actually Access Now
For the first time, the statistics are accumulating against a backdrop of disease-modifying treatment. Leqembi (lecanemab) received traditional FDA approval on July 6, 2023, for early symptomatic Alzheimer’s — meaning mild cognitive impairment or mild dementia — and is now available both as an IV infusion and as a subcutaneous formulation called Leqembi Iqlik, which can reduce the burden of twice-monthly infusion-center visits. Kisunla (donanemab), approved July 2, 2024, became the second traditionally approved anti-amyloid therapy. The tradeoff with both drugs is real and should be weighed carefully. They slow decline in early-stage disease; they do not stop or reverse it, and they do nothing for people in moderate or severe stages.
Both carry the risk of ARIA — amyloid-related imaging abnormalities, meaning brain swelling or microbleeds — and that risk is higher for people who carry the ApoE4 gene variant. Choosing treatment means committing to regular MRI monitoring and accepting a modest slowing of decline in exchange for meaningful medical risk, which is why genetic testing and a frank conversation with a neurologist come first. Diagnosis is changing too. In May 2025, the FDA cleared the first Alzheimer’s blood test — Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 plasma ratio — to help detect amyloid pathology in adults 50 and older who already have cognitive symptoms. Labcorp launched a commercial FDA-cleared blood test the same year. Compared with the previous options — a PET scan costing thousands of dollars or a spinal tap — a blood draw is dramatically cheaper and easier, though these tests are diagnostic aids for symptomatic patients, not general screening tools for the worried well.
What the Statistics Miss — Undercounting, Underdiagnosis, and the 65+ Caveat
Anyone quoting the 7.4 million figure should understand what it does and does not include. It is specifically an estimate of Americans age 65 and older with Alzheimer’s dementia. People with younger-onset Alzheimer’s — diagnosed in their 40s, 50s, or early 60s — are not in that count, and neither are the millions of Americans with mild cognitive impairment, some of whom will progress to dementia. Headlines that say “7 million Americans have Alzheimer’s” are directionally right but imprecise.
Underdiagnosis compounds the problem. Many people with dementia never receive a formal diagnosis, particularly in rural areas and in communities with less access to specialists — the same Black and Hispanic communities that carry higher disease risk are often diagnosed later, when treatment options like anti-amyloid drugs are no longer available because the disease has advanced past the early stage. That is a cruel asymmetry: the new therapies only work early, and the people at highest risk are the least likely to be diagnosed early. There is also a warning worth stating plainly for families: a statistic like “1 in 9 seniors” can create fatalism, but Alzheimer’s is not an inevitable part of aging. Most people over 65 — about 89 percent — do not have Alzheimer’s dementia, and memory changes that arrive suddenly or interfere with daily life warrant a medical workup, because some causes of cognitive symptoms (thyroid problems, medication interactions, depression, vitamin deficiencies) are treatable.
The Caregiver Statistics Behind the Patient Statistics
Every person counted in the 7.4 million typically has one or more people providing care, and the 2026 report quantifies that shadow workforce: more than 19 billion hours of unpaid care in a single year, valued at over $446 billion — a sum larger than the annual revenue of most Fortune 10 companies. A typical arrangement looks like a 58-year-old adult child managing a parent’s finances, meals, and doctor visits for years, escalating to round-the-clock supervision as the disease progresses.
The USC Schaeffer Center’s finding that only about 27 percent of dementia’s total cost runs through the formal health system underlines the same point from a different angle: dementia in America is, financially and practically, mostly a family affair. Caregivers experience elevated rates of depression, chronic stress, and their own health problems, which is why respite care, adult day programs, and caregiver support groups are treated by clinicians as part of the disease’s management, not an optional extra.
State and Regional Variation in Alzheimer’s Deaths
Alzheimer’s mortality is not evenly distributed across the country. CDC and National Center for Health Statistics data, which track Alzheimer’s death rates state by state, consistently show substantial variation — driven by differences in population age structure, diagnosis practices, death-certificate coding habits, and access to specialty care.
The CDC maintains state-level Alzheimer’s mortality statistics through its NCHS state health data program, and families researching care options can use those figures to understand how their state compares. The 116,022 official Alzheimer’s deaths recorded nationally in 2024 translate into very different local realities: states with older populations, such as those with large retiree communities, record disproportionately high shares of dementia deaths and correspondingly heavier demand on hospice, memory care, and Medicaid long-term care budgets.
Frequently Asked Questions
How many Americans have Alzheimer’s disease in 2026?
The Alzheimer’s Association’s 2026 Facts and Figures report estimates 7.4 million Americans age 65 and older are living with Alzheimer’s dementia. That count excludes younger-onset cases, so the all-ages total is higher.
Is Alzheimer’s becoming more common?
The number of Americans with Alzheimer’s is growing as the population ages, and is projected to reach 13.8 million by 2060 absent breakthroughs. Reported Alzheimer’s deaths rose 134% between 2000 and 2024, while deaths from heart disease, stroke, and HIV declined.
Who is at highest risk for Alzheimer’s?
Age is the biggest risk factor — 74% of people with the disease are 75 or older. Almost two-thirds of Americans with Alzheimer’s are women, older Black Americans are about twice as likely, and older Hispanic Americans about 1.5 times as likely, as older White Americans to have Alzheimer’s or another dementia.
Are there treatments for Alzheimer’s now?
Two FDA-approved anti-amyloid drugs — Leqembi (lecanemab, approved 2023) and Kisunla (donanemab, approved 2024) — can slow decline in early symptomatic Alzheimer’s. Both carry ARIA (brain swelling/microbleed) risk, especially for ApoE4 carriers, and neither stops or reverses the disease.
Is there a blood test for Alzheimer’s?
Yes. The FDA cleared the first Alzheimer’s blood test, Fujirebio’s Lumipulse G pTau 217/β-Amyloid 1-42 plasma ratio, in May 2025 for adults 50+ with cognitive symptoms. Labcorp launched a commercial FDA-cleared blood test the same year. These aid diagnosis in symptomatic patients; they are not general screening tools.
How much does dementia care cost in the United States?
The Alzheimer’s Association projects $409 billion in health and long-term care costs for 2026, with Medicare and Medicaid covering about 75%. A broader USC Schaeffer Center analysis put dementia’s total economic cost at roughly $818 billion, most of it borne by families rather than the formal health system.
